Literature DB >> 31025317

Significant association of DRD2 enhancer variant rs12364283 with heroin addiction in a Pakistani population.

Shagufta Jabeen1, Julia K Pinsonneault2, Wolfgang Sadee2, Sung-Ha Lee2, Muhammad Mobeen Zafar1, Muhammad Saqlain Raja1, Ghazala Kaukab Raja1.   

Abstract

The dopamine D2 receptor encoded by DRD2 has been implicated in multiple psychiatric disorders, mediated at least in part by two intronic variants affecting mRNA splicing, rs1076560 and rs2283265, and a less frequent enhancer variant, rs12364283, which increases DRD2 mRNA expression. This study tests whether these functionally validated variants confer susceptibility toward heroin addiction in a Pakistani population. A total of 540 heroin addicts and 467 healthy controls were genotyped, basic allele and genotype tests were performed. Neither rs1076560 nor rs2283265 significantly associated with heroin addiction. The enhancer rs12364283 occurs more frequently in heroin-dependent cases than controls (MAF 13% vs. 7%, respectively), revealing significant association with heroin addiction (p = 3.0E-06, OR 2.1). This study identifies rs12364283 of DRD2 as a potential risk factor for heroin addiction in the Pakistani study population. This enhancer variant had been shown to increase DRD2 mRNA expression, a possible factor in increased vulnerability to heroin addiction. Further studies are needed to validate this association of rs12364283.
© 2019 John Wiley & Sons Ltd/University College London.

Entities:  

Keywords:  DRD2; addiction; enhancer variant; genetics; opioids

Mesh:

Substances:

Year:  2019        PMID: 31025317      PMCID: PMC6699898          DOI: 10.1111/ahg.12322

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  15 in total

1.  Single nucleotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves.

Authors:  Audrey C Papp; Julia K Pinsonneault; Glen Cooke; Wolfgang Sadée
Journal:  Biotechniques       Date:  2003-05       Impact factor: 1.993

2.  Variants associated with common disease are not unusually differentiated in frequency across populations.

Authors:  Kirk E Lohmueller; Matthew M Mauney; David Reich; John M Braverman
Journal:  Am J Hum Genet       Date:  2005-11-16       Impact factor: 11.025

3.  Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs.

Authors:  M T Tsuang; M J Lyons; S A Eisen; J Goldberg; W True; N Lin; J M Meyer; R Toomey; S V Faraone; L Eaves
Journal:  Am J Med Genet       Date:  1996-09-20

4.  Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse.

Authors:  Robert A Moyer; Danxin Wang; Audrey C Papp; Ryan M Smith; Linda Duque; Deborah C Mash; Wolfgang Sadee
Journal:  Neuropsychopharmacology       Date:  2010-12-08       Impact factor: 7.853

5.  Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain.

Authors:  S S Kaalund; E N Newburn; T Ye; R Tao; C Li; A Deep-Soboslay; M M Herman; T M Hyde; D R Weinberger; B K Lipska; J E Kleinman
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

6.  Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants.

Authors:  Ajna Hamidovic; Andrea Dlugos; Andrew Skol; Abraham A Palmer; Harriet de Wit
Journal:  Exp Clin Psychopharmacol       Date:  2009-12       Impact factor: 3.157

7.  Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory.

Authors:  Ying Zhang; Alessandro Bertolino; Leonardo Fazio; Giuseppe Blasi; Antonio Rampino; Raffaella Romano; Mei-Ling T Lee; Tao Xiao; Audrey Papp; Danxin Wang; Wolfgang Sadée
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

8.  Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution.

Authors:  Alexandra Doehring; Nils von Hentig; Jochen Graff; Syavash Salamat; Michael Schmidt; Gerd Geisslinger; Sebastian Harder; Jörn Lötsch
Journal:  Pharmacogenet Genomics       Date:  2009-06       Impact factor: 2.089

9.  Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities.

Authors:  M T Tsuang; M J Lyons; J M Meyer; T Doyle; S A Eisen; J Goldberg; W True; N Lin; R Toomey; L Eaves
Journal:  Arch Gen Psychiatry       Date:  1998-11

10.  PTSD risk associated with a functional DRD2 polymorphism in heroin-dependent cases and controls is limited to amphetamine-dependent individuals.

Authors:  Elliot C Nelson; Andrew C Heath; Michael T Lynskey; Arpana Agrawal; Anjali K Henders; Lisa M Bowdler; Alexandre A Todorov; Pamela A F Madden; Elizabeth Moore; Louisa Degenhardt; Nicholas G Martin; Grant W Montgomery
Journal:  Addict Biol       Date:  2013-05-06       Impact factor: 4.280

View more
  1 in total

1.  Opioid Use Disorder and Alternative mRNA Splicing in Reward Circuitry.

Authors:  Spencer B Huggett; Ami S Ikeda; John E McGeary; Karla R Kaun; Rohan H C Palmer
Journal:  Genes (Basel)       Date:  2022-06-10       Impact factor: 4.141

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.